4 results
To assess the anti-tumor activity of LGX818/MEK162 in combination with third targeted agents after progression on LGX818/MEK162 combination therapy.
Primary objectives: 1) Phase Ib: To estimate the MTD or RP2D of INC280 in combination with gefitinib in NSCLC patients who have c-MET dysregulation. 2) Phase II: To estimate overall clinical activity of INC280 in combination with gefitinib in NSCLC…
The main objectives are to investigate the pharmacokinetic properties of DP tobramycin via the Cyclops® at different dosages in children with CF, together with the local tolerability.
The primary objectives of the trial are to:- Evaluate the efficacy of the PCL-based bulking agent treatment as determined by the Stamey Grading System (SGS). The SGS will be determined at baseline, 3, 6, 12, 18, and 24 months follow-up. - Evaluate…